Arvinas, Inc. (NASDAQ:ARVN) Insider Sells $1,670,250.00 in Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 25,000 shares of the stock in a transaction that occurred on Monday, April 5th. The shares were sold at an average price of $66.81, for a total transaction of $1,670,250.00. Following the completion of the transaction, the insider now directly owns 103,645 shares of the company’s stock, valued at approximately $6,924,522.45. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Ian Taylor also recently made the following trade(s):

  • On Tuesday, March 2nd, Ian Taylor sold 894 shares of Arvinas stock. The shares were sold at an average price of $77.45, for a total transaction of $69,240.30.

ARVN opened at $64.36 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.53 and a quick ratio of 6.53. The company’s 50-day moving average is $71.12 and its 200 day moving average is $54.24. Arvinas, Inc. has a fifty-two week low of $19.68 and a fifty-two week high of $92.77. The firm has a market capitalization of $3.15 billion, a P/E ratio of -25.14 and a beta of 2.14.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Sunday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.21). Arvinas had a negative net margin of 403.77% and a negative return on equity of 46.99%. The firm had revenue of $2.22 million for the quarter, compared to the consensus estimate of $7.46 million. On average, equities research analysts expect that Arvinas, Inc. will post -2.77 earnings per share for the current year.

Several equities analysts have recently issued reports on ARVN shares. The Goldman Sachs Group raised their price target on shares of Arvinas from $78.00 to $129.00 and gave the company a “buy” rating in a research note on Monday, December 14th. Oppenheimer lifted their target price on shares of Arvinas from $80.00 to $100.00 in a research note on Tuesday, January 19th. Wedbush lifted their target price on shares of Arvinas from $62.00 to $93.00 and gave the stock an “outperform” rating in a research note on Monday, December 14th. HC Wainwright reissued a “buy” rating and set a $100.00 target price (up previously from $60.00) on shares of Arvinas in a research note on Monday, December 14th. Finally, Cantor Fitzgerald lifted their target price on shares of Arvinas from $121.00 to $140.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 30th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Arvinas currently has an average rating of “Buy” and a consensus price target of $105.00.

A number of hedge funds have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System raised its position in Arvinas by 3.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 13,252 shares of the company’s stock worth $1,125,000 after acquiring an additional 400 shares during the period. IndexIQ Advisors LLC raised its position in Arvinas by 11.5% in the fourth quarter. IndexIQ Advisors LLC now owns 5,197 shares of the company’s stock worth $441,000 after acquiring an additional 536 shares during the period. Penserra Capital Management LLC raised its position in Arvinas by 178.3% in the fourth quarter. Penserra Capital Management LLC now owns 935 shares of the company’s stock worth $79,000 after acquiring an additional 599 shares during the period. First Mercantile Trust Co. bought a new stake in Arvinas in the fourth quarter worth about $59,000. Finally, State of Wisconsin Investment Board raised its position in Arvinas by 2.3% in the fourth quarter. State of Wisconsin Investment Board now owns 48,000 shares of the company’s stock worth $4,077,000 after acquiring an additional 1,100 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

See Also: What is total return in investing?

Insider Buying and Selling by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.